200 related articles for article (PubMed ID: 22761159)
1. Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.
Vaidyanathan V; Bastarrachea RA; Higgins PB; Voruganti VS; Kamath S; DiPatrizio NV; Piomelli D; Comuzzie AG; Parks EJ
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E624-34. PubMed ID: 22761159
[TBL] [Abstract][Full Text] [Related]
2. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid flux and oxidation are increased by rimonabant in obese women.
Backhouse K; Sarac I; Shojaee-Moradie F; Stolinski M; Robertson MD; Frost GS; Bell JD; Thomas EL; Wright J; Russell-Jones D; Umpleby AM
Metabolism; 2012 Sep; 61(9):1220-3. PubMed ID: 22445512
[TBL] [Abstract][Full Text] [Related]
4. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.
Flamment M; Gueguen N; Wetterwald C; Simard G; Malthièry Y; Ducluzeau PH
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1162-70. PubMed ID: 19724020
[TBL] [Abstract][Full Text] [Related]
5. Does rimonabant independently affect free fatty acid and glucose metabolism?
Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M
J Clin Endocrinol Metab; 2012 Mar; 97(3):819-27. PubMed ID: 22170727
[TBL] [Abstract][Full Text] [Related]
6. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
7. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
[TBL] [Abstract][Full Text] [Related]
8. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
[TBL] [Abstract][Full Text] [Related]
9. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
[TBL] [Abstract][Full Text] [Related]
10. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis.
O'Hare JD; Zielinski E; Cheng B; Scherer T; Buettner C
Diabetes; 2011 Apr; 60(4):1055-62. PubMed ID: 21447652
[TBL] [Abstract][Full Text] [Related]
11. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P
Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567
[TBL] [Abstract][Full Text] [Related]
12. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
Bennetzen MF; Nielsen MP; Richelsen B; Pedersen SB
Obesity (Silver Spring); 2008 Nov; 16(11):2451-5. PubMed ID: 18719671
[TBL] [Abstract][Full Text] [Related]
13. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.
Richey JM; Woolcott OO; Stefanovski D; Harrison LN; Zheng D; Lottati M; Hsu IR; Kim SP; Kabir M; Catalano KJ; Chiu JD; Ionut V; Kolka C; Mooradian V; Bergman RN
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1311-8. PubMed ID: 19366874
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
Bajzer M; Olivieri M; Haas MK; Pfluger PT; Magrisso IJ; Foster MT; Tschöp MH; Krawczewski-Carhuatanta KA; Cota D; Obici S
Diabetologia; 2011 Dec; 54(12):3121-31. PubMed ID: 21987346
[TBL] [Abstract][Full Text] [Related]
15. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
16. Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats.
Mølhøj S; Hansen HS; Schweiger M; Zimmermann R; Johansen T; Malmlöf K
Eur J Pharmacol; 2010 Nov; 646(1-3):38-45. PubMed ID: 20727879
[TBL] [Abstract][Full Text] [Related]
17. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.
Bell-Anderson KS; Aouad L; Williams H; Sanz FR; Phuyal J; Larter CZ; Farrell GC; Caterson ID
Int J Obes (Lond); 2011 Dec; 35(12):1539-48. PubMed ID: 21386801
[TBL] [Abstract][Full Text] [Related]
18. Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition.
Koolman AH; Bloks VW; Oosterveer MH; Jonas I; Kuipers F; Sauer PJ; van Dijk G
Int J Obes (Lond); 2010 Feb; 34(2):374-84. PubMed ID: 19844210
[TBL] [Abstract][Full Text] [Related]
19. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
[TBL] [Abstract][Full Text] [Related]
20. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction.
Lipina C; Vaanholt LM; Davidova A; Mitchell SE; Storey-Gordon E; Hambly C; Irving AJ; Speakman JR; Hundal HS
Aging Cell; 2016 Apr; 15(2):325-35. PubMed ID: 26757949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
